• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
        • NTM Lung Disease
        • Bronchiectasis
        • Pulmonary Arterial Hypertension
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Programs
      • Pipeline
      • Clinical Trials
      • Our Research Team
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home/Science/Investigator-Initiated Research

Investigator-Initiated Research

Helping scientists investigate the unanswered

We will consider providing financial support and/or product supply for novel research proposals that answer important scientific and medical questions in our areas of interest. Grant recipients have the right to publish the results of the study and maintain full control over the research project objectives, design, conduct, data analysis, and interpretation.


Contact us with any questions about requirements and procedures

Submit a request for grant support

Areas of interest

Amikacin Liposome Inhalation Suspension and Pulmonary Infections

Interventional Amikacin Liposome Inhalation Suspension in Nontuberculous Mycobacterial (NTM) Lung Disease

  1. NTM in different population
    1. By disease severity (e.g., using a severity index)
    2. By species
    3. Transplant population – pre- and post-transplant
    4. Mixed NTM infection
    5. Cavitary disease
  2. Assessment of disease
    1. Biomarkers and genetic markers for NTM diagnosis and disease progression
    2. Radiographic change and disease response to amikacin liposome inhalation suspension
    3. Culture assessment
  3. Adverse event management/medication adherence 

Amikacin Liposome Inhalation Suspension in Non-NTM Pulmonary Infections

  1. Gram-negative infections
  2. Acute pneumonia (ventilator-associated pneumonia)
  3. Multi-drug resistant tuberculosis (MTB or MDR-TB)

Disease State/Mechanism of Disease

  1. Novel models of infection
  2. Understanding relapse/reinfection

Burden of Illness of NTM Lung Disease

  1. Indirect costs of NTM lung disease
  2. Impact of NTM lung disease on patient functioning and productivity
  3. Epidemiology of Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) infections
  4. Barriers to appropriate and timely screening of NTM lung disease
  5. Barriers to appropriate guideline-based treatment initiation and treatment adherence with treatment for NTM lung disease

Bronchiectasis and Other Neutrophil-Related Disorders

Disease State/Mechanism of Disease

  1. Neutrophil-related pulmonary disease
  2. Levels of neutrophil serine protease (NSP) biomarkers of disease severity/burden in patients with autoimmune or inflammatory disease
  3. Natural history, clinical course, and progression of the disease

Footer

Insmed
LinkedInTwitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
      • NTM Lung Disease
      • Bronchiectasis
      • Pulmonary Arterial Hypertension
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Programs
    • Pipeline
    • Clinical Trials
    • Our Research Team
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2022 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
      • NTM Lung Disease
      • Bronchiectasis
      • Pulmonary Arterial Hypertension
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Programs
    • Pipeline
    • Clinical Trials
    • Our Research Team
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filiings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2021 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy